Sema4 IPO
Sema4 is a health intelligence company that combines genomic data with clinical information to provide insights for healthcare providers, researchers, and patients. The company offers genetic testing services, data analytics platforms, and clinical decision support tools. Sema4 was spun out from Mount Sinai Health System and focuses on translating genomic data into actionable healthcare insights.
Key Facts
| Industry | Genomics |
| Founded | 2017 |
| Headquarters | Stamford, CT |
| Employees | ~1,000 |
| Website | sema4.com |
| Funding | Public via SPAC merger in 2021. Previously raised ~$800M |
About Sema4
Sema4 is a patient-centered health intelligence company that leverages genomics, clinical data, and AI to advance precision medicine and improve health outcomes. The company was spun out from Mount Sinai Health System and combines laboratory testing services with data analytics platforms to help healthcare providers make more informed treatment decisions. Sema4's offerings include reproductive health testing, oncology diagnostics, and population health analytics, with a focus on using large-scale data to identify patterns and improve patient care.
The company went public via SPAC in 2021 but has faced significant operational and financial challenges, including leadership changes, workforce reductions, and strategic pivots. Sema4 has struggled to achieve profitability despite the growing market for precision medicine and genomic testing. The company has been working to streamline operations and focus on its most promising business segments while dealing with competitive pressures from larger, more established players in the genomics space.
IPO Status
Sema4 went public in February 2021 through a SPAC merger with CM Life Sciences, trading on NASDAQ under the ticker symbol SMFR. The transaction valued the company at approximately $2.5 billion and provided significant funding for expansion. However, the company has faced challenges as a public entity, including declining stock performance and operational difficulties. In late 2023, Sema4 faced significant financial distress and underwent major restructuring, including layoffs and asset sales. The company's stock has traded well below its initial public valuation, reflecting the challenges in the genomics and health data analytics market.
Competitors
Frequently Asked Questions
Does Sema4 have a stock?
Yes, Sema4 became a public company in February 2021 through a SPAC merger. The company trades on NASDAQ under the ticker symbol SMFR.
When is the Sema4 IPO date?
Sema4 completed its public debut in February 2021 through a merger with CM Life Sciences SPAC, valued at approximately $2.5 billion at the time. The company has been publicly traded since then.
How can I buy Sema4 stock?
You can buy Sema4 stock through any brokerage account as it trades publicly on NASDAQ under the ticker symbol SMFR. However, potential investors should be aware of the company's recent financial challenges and restructuring.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts